Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Genfit to study elafibranor in Phase II trial for paediatric NASH

Non-alcoholic fatty liver disease (NAFLD) has become the most common liver condition diagnosed in children and adolescents. Credit: LillyCantabile via Pixabay.



  • Genfit to study elafibranor in Phase II trial for paediatric NASH

Go Top